Endothelin receptor antagonists
Endothelin receptor antagonists has been studied in 17 papers since 2022: 2 observational studies in people, 15 reviews; 13 in the past year. The newest paper, Nov 12, 2026: “Endothelin-1 and the Fibrinolytic System in Obesity: A Mechanistic Account of Hypofibrinolysis and Cardiometabolic Risk”.
6 new papers in 30 daysSee all 17 papers on endothelin receptor antagonists
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“The odds of ERA exposure were 63.2% lower”
- 1 lab in 1 country
- Humans2
What did studies of endothelin receptor antagonists find?
2Studies of endothelin receptor antagonists measured 2 outcomes: albuminuria and hypertension.
Albuminuria
downin humans1
1 study
Albuminuria
downin humans1
Endothelin receptor antagonists decrease albuminuria in humans.
“an antagonist of type 1 endothelin receptor (ET1R) with proven efficacy to reduce albuminuria and proteinuria”
Review
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Journal of clinical medicine
Hypertension
downin reviews1
1 study
Hypertension
downin reviews1
Endothelin receptor antagonists decrease hypertension (caused by small molecule tyrosine kinase inhibitors).
“Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)”
Reviewcaused by small molecule tyrosine kinase inhibitors
Frontiers in pharmacology
What is endothelin receptor antagonists linked with?
1Studies link endothelin receptor antagonists with Alzheimer's disease and related dementias.
Alzheimer's disease and related dementias
downin humans1
1 study
Alzheimer's disease and related dementias
downin humans1
Endothelin receptor antagonists are associated with Alzheimer's disease and related dementias in humans (Pulmonary hypertension) (Odds of exposure 63.2% lower in ADRD cases than controls).
“The odds of ERA exposure were 63.2% lower”
HumansPulmonary hypertension
PloS one